AstraZeneca and Merck reveal complete results from phase three SOLO3 LYNPARZA trial.

M2 PHARMA-June 5, 2019-AstraZeneca and Merck reveal complete results from phase three SOLO3 LYNPARZA trial

(C)2019 M2 COMMUNICATIONS

United Kingdom-based AstraZeneca and United States-based Merck have revealed complete results from the phase three SOLO3 trial that assessed LYNPARZA, compared to chemotherapy intended for the treatment of platinum-sensitive relapsed patients with germline BRCA1/2-mutated advanced ovarian cancer, who have received two more prior lines of chemotherapy, it was reported yesterday.

The results were showcased at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago.

The companies said that the results from the trial indicated a statistically-significant and clinically-meaningful improvement in objective response rate in the LYNPARZA arm compared to the chemotherapy arm (ORR; 72.2% for LYNPARZA vs 51.4% for chemotherapy; 95% CI: 1.40 to 4.58; p=0.002). The key secondary endpoint of progression-free survival was also significantly increased in the LYNPARZA arm (13.4 months) compared to the chemotherapy arm (9.2 months; PFS HR 0.62 [p=0.013]).

((Comments on this story may be sent to info@m2.com))